KOD - Kodiak Sciences: Potential For Comeback After Trial Setback

• Results from the BEACON study, which is using KSI-301 for the treatment of patients with retinal vein occlusion, are expected by Q3 of 2022.
• The global retinal vein occlusion market is estimated to be worth $25.66 billion by 2028.
• Additional trial readouts using new dosing schedules such as diabetic macular edema, non-proliferative diabetic retinopathy, and treatment naive Wet-AMD are expected in 2023.
• Kodiak Sciences had $671.7 million in cash as of March 31, 2022, enough cash to fund operations for at least the next 12 months.

For further details see: